Rifampicin (RIF) Monotherapy (4 months for Latent TB Infection)
Treatment for Drug Susceptible Tuberculosis
Typical Dosage: Rifampicin 600mg daily
Effectiveness
77%
Safety Score
68%
Clinical Trials
25
Participants
20K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
68
DangerousModerateSafe
Treatment Details
Dosage Range
Rifampicin 600mg daily
Time to Effect
Prevention initiated within weeks, protective effect over years
Treatment Duration
4 months
Evidence Quality
HIGHNumber Needed to Treat (NNT)
15(Treat 15 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
150(Treat 150 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$120
Monitoring:$150
Side Effect Mgmt:$50
Total Annual:$320
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$25,000/QALY
QALYs Gained
0.1
Comparison vs Isoniazid (INH) Monotherapy (9 months)
Cost Difference
$-5/year
Less expensive
QALY Difference
0.00 QALYs
Same outcomes
Dominance
DOMINATESBetter + cheaper
Rifampicin (RIF) Monotherapy (4 months for Latent TB Infection) Outcomes
for Drug Susceptible Tuberculosis
Efficacy Outcomes
Overall Effectiveness
+77%
Common Side Effects
GI upset
+10%
Orange/red discoloration of body fluids
+100%
Hepatotoxicity
+3%
Rash
+5%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov